Considerations for diabetes: Treatment with insulin pen devices

American Journal of Therapeutics

Volumn 20, Issue 6, 2013, Pages 694-702

  Cuddihy, Robert M ^a,b   Borgman, Sarah K ^b  

^a SANOFI   (France)

^b INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

Accuracy; Advantages; Barriers; Diabetes; Insulin pen

Indexed keywords

INSULIN; ANTIDIABETIC AGENT;

ARTICLE; DIABETES MELLITUS; GENERAL MEDICAL DEVICE; HUMAN; INSULIN INJECTION PEN; INSULIN TREATMENT; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYRINGE; VIAL; COMPARATIVE STUDY; DRUG COST; DRUG DELIVERY SYSTEM; ECONOMICS; HEALTH CARE COST; INSULIN DEPENDENT DIABETES MELLITUS; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; REVIEW; SELF CARE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG DELIVERY SYSTEMS; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MEDICATION ADHERENCE; PATIENT PREFERENCE; SELF CARE; SYRINGES;

EID: 84904374881     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318217a5e3     Document Type: Article

References (70)

1. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care. 2010;33(suppl 1): S11-S61.
2. Turner RC, Cull CA, Frighi V, et al. and the UK Prospective Diabetes Study Group (UKPDS). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
3. Wright A, Burden ACF, Paisey RB, et al and the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25: 330-336.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
5. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007; 22:453-458.
6. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002;28:52-60.
7. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4:165-174.
8. Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther. 2010;12(suppl 1): S79-S85.
9. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
10. Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone. 2006;8(suppl 2):S19-S26.
11. Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulin-based versus triple oral therapy for newly-diagnosed type 2 diabetes: which is better? Diabetes Care. 2009;32:1789-1795.
12. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med. 2008;120:172-179.
13. Brunton S. Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med. 2008;121(suppl 6):S35-S41.
14. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32(suppl 1): 9S-18S.
15. Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34:511-517.
16. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935-982.
17. Spollett G. Insulin devices: addressing barriers to insulin therapy with the ideal pen. Diabetes Educ. 2008;34: 957-960, 963, 967.
18. Oliveria SA, Menditto LA, Ulcickas YM, et al. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23:3105-3112.
19. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998;79:59-62.
20. Haller H. Postprandial glucose and vascular disease. Diabet Med. 1997;14(suppl 3):S50-S56.
21. Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33:240-245.
22. Burdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics. 2004;113: e221-e224.
23. Randlov J, Poulsen JU. How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study. J Diabetes Sci Technol. 2008;2:229-235.
24. Asakura T, Seino H, Nakano R, et al. A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther. 2009;11: 657-661.
25. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43:69-74.
26. Ignaut DA, Schwartz SL, Sarwat S, et al. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35: 789-798.
27. Ignaut DA, Opincar M, Lenox S. FlexPen and KwikPen prefilled insulin devices: a laboratory evaluation of ergonomic and injection force characteristics. J Diabetes Sci Technol. 2008;2:533-537.
28. Lteif A, Schwenk WF Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999;22:137-140.
29. Luijf YM, DeVries JH. Dosing accuracy of insulin pens versus conventional syringes and vials. Diabetes Technol Ther. 2010;12(suppl 1):S73-S77.
30. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther. 2008;10:247-256.
31. Albano S. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. The ORBITER Study Group. Acta Biomed. 2004;75: 34-39.
32. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther. 2010;27: 94-104.
33. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27:948-962.
34. Coscelli C, Lostia S, Lunetta M, et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 1995;28:173-177.
35. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28:1712-1725.
36. Davis S, Wei W, Garg S. Initiating insulin glargine (GLAR) with a pen (Solostar®) vs. a vial: impact on utilization and outcomes in a national managed care database. Poster presented at: the 70th Scientific Sessions of the American Diabetes Association; June 25-29, 2010; Orlando, FL. Poster 541-P.
37. Polonsky WH, Jackson RA. What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22: 147-150.
38. Dunning T. Insulin delivery devices. Austr Prescr. 2002;25: 136-138.
39. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20:486-496.
40. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12(suppl 1):S101-S108.
41. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29(pt 1):1294-1305.
42. Davis EM, Christensen CM, Nystrom KK, et al. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65:1347-1357.
43. Lee IT, Liu HC, Liau YJ, et al. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract. 2009;15:699-703.
44. Nicolucci A, Cucinotta D, Squatrito S, et al. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2009;19:45-53.
45. Fox C, McKinnon C, Wall A, et al. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diabetes Int. 2002;19:104-107.
46. Stockl K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin. 2007;23:133-146.
47. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004;19:330-337.
48. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836-2848.
49. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26:1498-1505.
50. Shelmet J, Schwartz S, Cappleman J, et al. Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Res Clin Pract. 2004;63: 27-35.
51. Davis EM, Bebee A, Crawford L, et al. Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educ. 2009;35:799-809.
52. Carter J, Roberts A. Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin. 2008;24:2741-2749.
53. Brown AW. Clinicians' guide to diabetes gadgets and gizmos. Clin Diabetes. 2008;26:66-71.
54. Boyle ME. Optimizing the treatment of type 2 diabetes using current and future insulin technologies. MEDSURG Nursing. 2008;17:383-390.
55. Chauhan KG, Mukadam A, Jahagirdar KH, et al. Advances in insulin delivery devices. J Pharm Res. 2009; 2:1515-1520.
56. Pfutzner A, Reimer T, Hohberg C, et al. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24:2545-2549.
57. ClikSTAR a new reusable insulin pen for use with Lantus and Apidra® approved in EU and Canada. Available at: http://en.sanofi-aventis.com/press/press-releases/2009/ppc-26431.asp. Accessed September 30, 2009.
58. Friedrichs A, Korger V, Adler S. Injection force (IF) of reusable insulin pens: Novopen 4, Lilly Luxura (LL), Berlipen (BP), and Clikstar (CS). Poster presented at: the 70th Scientific Sessions of the American Diabetes Association; June 25-29, 2010; Orlando, FL. Poster 529-P
59. Krzywon M, Abdel-Tawab M, vanderBurg T, et al. Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin. 2010;26:901-905.
60. Burg T, Fuhr U, Schubert-Zsilavecz M, et al. Study on the dosing accuracy of common disposable insulin pens. Poster presented at: the 70th Scientific Sessions of the American Diabetes Association; June 25-29, 2010; Orlando, FL.
61. Friedrichs A. Dose accuracy of SoloSTAR and FlexPen as assessed in a clinical setting. Diabetes Technol Ther. 2009;11: 609-613.
62. Penfornis A, Horvat K. Dose accuracy comparison between SoloSTAR and FlexPen at three different dose levels. Diabetes Technol Ther. 2008;10:359-362.
63. Clark PE, Valentine V, Bodie JN, et al. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens. Curr Med Res Opin. 2010;26: 1745-1753.
64. Haak T, Edelman S, Walter C, et al. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29:650-660.
65. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31:430-432.
66. Miles P. A practical guide to insulin pens. Nurs Times. 2006;102:53-54.
67. Lakshmanadoss U, Ayyappan S, Jain A, et al. The broken pen penalty. Diabetes Technol Ther. 2010;12:241-243.
68. Food and Drug Administration. Information for healthcare professionals: risk of transmission of blood-borne pathogens from shared use of insulin pens. Available at: http://www.fda.gov/Drugs/DrugSafety/Postmarket-DrugSafetyInformationforPatientsandProviders/Drug-SafetyInformationforHealthcareProfessionals/ucm1333 52.htm. Accessed January 14, 2011.
69. Smith DE, Spinasanta S. Insulin delivery: what's the best way to inject insulin? Available at: http://www.endocri neweb.com/guides/insulin/insulin-delivery. Accessed March 12, 2009.
70. Smith DE, Spinasanta S. How to store your insulin: tips on insulin storage. Available at: http://www.endocrineweb. com/guides/insulin/how-store-your-insulin. Accessed January 14, 2011.